Advertisement

Investigational New Drugs

, 27:583 | Cite as

Wound healing delay after central venous access following DCF/VEGF-trap therapy

  • Charles FertéEmail author
  • Christophe Massard
  • Christian Moldovan
  • Eric Desruennes
  • Yohann Loriot
  • Jean-Charles Soria
SHORT REPORT

Summary

Hypertension, proteinuria, thromboembolic or bleeding events are well-recognized complications occurring while targeting VEGF pathway. Wound healing dysfunctions have also been described in patients undergoing major surgery. For the first time, we report wound healing delay after central venous access following DCF-VEGF-Trap. VEGF-Trap may affect both angiogenesis and reepithelialization which are necessary to the normal repair process.

Keywords

VEGF-Trap Wound healing Central venous access 

References

  1. 1.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342 doi: 10.1056/NEJMoa032691 CrossRefPubMedGoogle Scholar
  2. 2.
    Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91(3):173–180 doi: 10.1002/jso.20301 CrossRefPubMedGoogle Scholar
  3. 3.
    Singer AJ, Clark RA (1999) Cutaneous wound healing. N Engl J Med 341(10):738–746 doi: 10.1056/NEJM199909023411006 CrossRefPubMedGoogle Scholar
  4. 4.
    Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF (2008) Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11(2):109–119 doi: 10.1007/s10456-008-9099-z CrossRefPubMedGoogle Scholar
  5. 5.
    Ono M (2008) Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 99(8):1501–1506 doi: 10.1111/j.1349-7006.2008.00853.x CrossRefPubMedGoogle Scholar
  6. 6.
    Riely GJ, Miller VA (2007) Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res 13(15 Pt 2):s4623–s4627 doi: 10.1158/1078-0432.CCR-07-0544 CrossRefPubMedGoogle Scholar
  7. 7.
    Fan X, Krieg S, Kuo CJ, Wiegand SJ, Rabinovitch M, Druzin ML, Brenner RM, Giudice LC, Nayak NR (2008) VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. FASEB J 22(10):3571–3580 doi: 10.1096/fj.08-111401 CrossRefPubMedGoogle Scholar
  8. 8.
    Penel N, Neu JC, Clisant S, Hoppe H, Devos P, Yazdanpanah Y (2007) Risk factors for early catheter-related infections in cancer patients. Cancer 110(7):1586–1592 doi: 10.1002/cncr.22942 CrossRefPubMedGoogle Scholar
  9. 9.
    Poorter RL, Lauw FN, Bemelman WA, Bakker PJ, Taat CW, Veenhof CH (1996) Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of Chemotherapy. Eur J Cancer 32A(13):2262–2266 doi: 10.1016/S0959-8049(96)00274-2 CrossRefPubMedGoogle Scholar
  10. 10.
    Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB (2005) Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 11(19 Pt 1):6966–6971CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Charles Ferté
    • 1
    Email author
  • Christophe Massard
    • 1
  • Christian Moldovan
    • 1
  • Eric Desruennes
    • 2
  • Yohann Loriot
    • 1
  • Jean-Charles Soria
    • 1
  1. 1.Department of MedicineInstitut Gustave Roussy, Phase I unit (SITEP)VillejuifFrance
  2. 2.Department of AnaesthesiologyInstitut Gustave RoussyVillejuifFrance

Personalised recommendations